FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

被引：30

作者：

Gane, E. J. ^{[1
]}

Roberts, S. K. ^{[2
]}

Stedman, C. ^{[3
]}

Angus, P. W. ^{[4
]}

Ritchie, B. ^{[5
]}

Elston, R.

Ipe, D. ^{[6
]}

Baher, L. ^{[6
]}

Morcos, P. ^{[6
]}

Najera, I. ^{[6
]}

Mannino, M. ^{[6
]}

Brennan, B. ^{[6
]}

Berrey, M. ^{[7
]}

Bradford, W. ^{[8
]}

Yetzer, E. ^{[6
]}

Shulman, N. ^{[6
]}

Smith, P. F. ^{[6
]}

机构：

[1] Auckland Clin Studies, Auckland, New Zealand

[2] The Alfred, Melbourne, Vic, Australia

[3] Christchurch Clin Studies, Christchurch, New Zealand

[4] Austin Hosp, Heidelberg, Vic 3084, Australia

[5] Royal Adelaide Hosp, Adelaide, SA 5000, Australia

[6] Roche Palo Alto LLC, Palo Alto, CA USA

[7] Pharmasset Inc, Princeton, NJ USA

[8] Intermune Inc, Brisbane, CA USA

来源：

关键词：

D O I：

10.1016/S0168-8278(09)61048-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1046

引用

页码：S380 / S380

页数：1